BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) and AstraZeneca (NYSE: AZN) today announced plans for two additional randomized Phase 2 trials for AZD6244 (ARRY-886). The trials, which will begin during the second half of 2008, will test AZD6244 in combination with a cytotoxic chemotherapeutic agent; one trial will be in melanoma patients and the other in non small cell lung cancer patients. These plans are based upon AZD6244’s activity as a single agent in previous monotherapy Phase 2 trials and on data from multiple preclinical studies. The data from these earlier clinical trials will be presented at the forthcoming American Society of Clinical Oncology Annual Meeting.
